30
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Research for new drugs for elimination of onchocerciasis in Africa

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Onchocerciasis is a parasitic, vector borne disease caused by the filarial nematode Onchocerca volvulus. More than 99% of the population at risk of infection live in Africa. Onchocerciasis control was initiated in West Africa in 1974 with vector control, later complemented by ivermectin mass drug administration and in the other African endemic countries in 1995 with annual community directed treatment with ivermectin (CDTI.) This has significantly reduced infection prevalence. Together with proof-of-concept for onchocerciasis elimination with annual CDTI from foci in Senegal and Mali, this has resulted in targeting onchocerciasis elimination in selected African countries by 2020 and in 80% of African countries by 2025. The challenges for meeting these targets include the number of endemic countries where conflict has delayed or interrupted control programmes, cross-border foci, potential emergence of parasite strains with low susceptibility to ivermectin and co-endemicity of loiasis, another parasitic vector borne disease, which slows down or prohibits CDTI implementation. Some of these challenges could be addressed with new drugs or drug combinations with a higher effect on Onchocerca volvulus than ivermectin. This paper reviews the path from discovery of new compounds to their qualification for large scale use and the support regulatory authorities provide for development of drugs for neglected tropical diseases. The status of research for new drugs or treatment regimens for onchocerciasis along the path to regulatory approval and qualification for large scale use is reviewed. This research includes new regimens and combinations of ivermectin and albendazole, antibiotics targeting the O. volvulus endosymbiont Wolbachia, flubendazole, moxidectin and emodepside and discovery of new compounds.

          Highlights

          • Challenges for onchocerciasis elimination requiring new drugs.

          • Summary of path from discovery to qualification of drugs for human use.

          • Regulatory support and incentives for development of drugs for neglected diseases.

          • Development of new dose regimens, drug combinations and new drugs against O. volvulus.

          Related collections

          Most cited references141

          • Record: found
          • Abstract: found
          • Article: not found

          Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study.

          Ivermectin has been used for onchocerciasis control since 1987. Because of the long-term use of this drug and the development of resistance in other nematodes, we have assessed Onchocerca volvulus burdens, effectiveness of ivermectin as a microfilaricide, and its effect on adult female worm reproduction. For the first phase of the study, 2501 individuals in Ghana, from 19 endemic communities who had received six to 18 annual rounds of ivermectin and one ivermectin naive community, were assessed for microfilarial loads 7 days before the 2004 yearly ivermectin treatment, by means of skin snips, and 30 days after treatment to assess the ivermectin microfilaricidal action. For the second phase, skin snips were taken from 342 individuals from ten communities, who were microfilaria positive at pretreatment assessment, on days 90 and 180 after treatment, to identify the effects of ivermectin on female worm fertility, assessed by microfilaria repopulation. 487 (19%) of the 2501 participants were microfilaria positive. The microfilaria prevalence and community microfilarial load in treated communities ranged from 2.2% to 51.8%, and 0.06 microfilariae per snip to 2.85 microfilariae per snip, respectively. Despite treatment, the prevalence rate doubled between 2000 and 2005 in two communities. Microfilaria assessment 30 days after ivermectin treatment showed 100% clearance of microfilaria in more than 99% of people. At day 90 after treatment, four of ten communities had significant microfilaria repopulation, from 7.1% to 21.1% of pretreatment counts, rising to 53.9% by day 180. Ivermectin remains a potent microfilaricide. However, our results suggest that resistant adult parasite populations, which are not responding as expected to ivermectin, are emerging. A high rate of repopulation of skin with microfilariae will allow parasite transmission, possibly with ivermectin-resistant O volvulus, which could eventually lead to recrudescence of the disease.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Phenotypic Evidence of Emerging Ivermectin Resistance in Onchocerca volvulus

            Introduction Ivermectin (Mectizan) has been in operational use for the control of human onchocerciasis in the former Onchocerciasis Control Programme in West Africa (OCP) areas since 1987 and is still the drug of choice for the African Programme for Onchocerciasis Control (APOC) and the Onchocerciasis Elimination Programme for the Americas (OEPA). A single dose of ivermectin rapidly kills skin microfilariae (mf) and inhibits microfilarial release by adult female worms, possibly because of paralysis of the lower uterus [1]. These effects result in a rapid decline in skin microfilarial counts, an accumulation of degenerating intra-uterine microfilariae and a long-lasting suppression of Onchocerca volvulus microfilaridermias [2]. However, the inhibition of mf release is reversible by six months resulting in the reappearance of microfilariae in the skin (repopulation) and after a further six months a restitution of a proportion of the initial load (recovery) [2]. A proportion of ivermectin exposed female worms do not resume reproductive activity even after one year [1] and this can persist for up to 18 months after treatment [3]. The prolonged microfilarial suppressant effect of ivermectin has beneficial effects on morbidity and on parasite transmission. Several studies [1], [4], [5], [6], [7], [8] have demonstrated that multiple treatments with ivermectin have marked suppressive effects on embryogenesis consistent with some cumulative effect of ivermectin treatments on microfilarial production. Quantitative estimates have ranged from an irreversible decline in microfilarial production of ∼30% after five annual treatments [9], a reduction in the productivity index of 90% or more after 10 six-monthly doses over 6 years [10], to arrest of development at the single cell stage after four or five six-monthly doses [11]. Recently, the cumulative effect of ivermectin on microfilarial production by O. volvulus has been questioned [12] based on mathematical modeling, with a number of necessary assumptions, of data generated in three Guatemalan villages that were subjected to five 6-monthly treatments. The conclusions from this study are, however, not consistent with data generated previously in Africa. Despite the varying dosage schemes, methodologies, criteria of assessment and interpretation of results that have been used, it is evident that the presence of a significant proportion of adult female worms producing viable microfilariae 3 to 6 months after treatment, following multiple doses of IVM, is inconsistent with a normal response. A sub-optimal response is manifested as higher than expected skin microfilaria counts at various time points post treatment. Awadzi and others [13] have proposed that for effective response of O. volvulus to IVM, the mf load in a patient one year after the last IVM treatment should not be >10 mf/snip following nine or more years of annual treatments. Despite previous African experience there are current reports of persistent, moderately high microfilaridermias after repeated ivermectin treatments [13], [14], [15]. These reports suggest that a population of adult female worms may have been selected that responds poorly to ivermectin. The development of resistance to ivermectin and other macrocyclic lactone anthelmintics has become widespread and is increasing in nematode parasites of sheep, goats and cattle, including Haemonchus contortus and Cooperia onchophora [16], [17], [18], [19]. With the distribution of more than 400 million doses of ivermectin as the only drug for mass onchocerciasis control in Africa [20] and with some communities having received more than 19 annual doses, it would not be surprising that the genetic selection [21], [22], [23], [24] observed in O. volvulus with IVM treatment was indicative of the development of ivermectin resistance in this parasite. We have previously reported moderately high early repopulation of skin with microfilariae by some populations of adult O. volvulus [15]. Following this report, we have reassessed the differences between O. volvulus populations showing poor responses and those showing good responses to ivermectin using various indicators of skin microfilarial repopulation, nodule and worm viability, adult worm densities, and female worm fertility in the original 10 endemic communities. Methods Study Design This was a randomized, open 21 month longitudinal study involving two annual ivermectin treatments, serial skin snipping and nodulectomies in the communities under a study that was carried out between October, 2004 and June, 2006. Skin microfilarial profiles were assessed in onchocerciasis affected patients at various time-points pre- and post-treatment to determine skin mf repopulation and, at one year post treatment, the microfilaria recovery rates. At the end of the study (90 days after a second annual treatment during the study), nodules containing adult Onchocerca volvulus were surgically removed and digested to extract adult worms. Embryogrammes were constructed to assess the reproductive status of the adult female worms. A summary of the study design and conduct is shown in Figure 1. 10.1371/journal.pntd.0000998.g001 Figure 1 Study design. Design for the entire study, showing time points used for examination of various parameters and the study populations at each phase of the study. Study Population and Area, Subject Eligibility and Selection The study was carried out in 10 onchocerciasis endemic communities located in three Districts in Ghana; Kintampo and Atebubu Districts in the Brong-Ahafo Region, and Gonja East District in the Northern Region. The criteria for selection of the communities have been detailed previously [15] and for the 9 communities that had received multiple treatments include: good written documentation on annual community treatment coverage, good community and individual treatment history, at least one survey over the previous 6 yrs (prevalence, community microfilarial load or both), average treatment coverage ≥50% in the previous 5 years, uninterrupted annual treatment over the previous 6 years and ivermectin treatment within the previous 10–12 months. Additionally, communities had to be accessible by road throughout the entire study period, especially during the period for nodulectomies. One community was ivermectin-naïve prestudy. Ethical approval for the study was obtained from the Institutional Review Board of Noguchi Memorial Institute for Medical Research, Ghana and the Ethical Review Board of McGill University, Canada. The informed consent procedure involved a durbar (meeting with the chief, elders and the entire community) with the study population at which the study design, investigative procedures and the risks and benefits of participation were outlined by the principal investigator in English and in the local language through an interpreter. Unlimited time was allowed for questions and explanations. After the durbar individuals who were interested in participation met with the investigator and interpreter individually and the contents of the consent form were explained in detail. After further questions and explanations, each subject signed or thumb-printed an informed consent form that testified to the fact that they had been told the details of the study, any questions they had asked had been answered to their satisfaction and that they freely consented to participate in the study. Investigative Procedures Subjects were aged between 18–65 years, had lived in the communities for at least ten years and, with the exception of the prestudy ivermectin-naïve, had received between 10 and 19 annual doses of IVM confirmed by interviews of participants and community ivermectin distributors, and examination of written treatment records, and had been skin snip positive for O. volvulus at the beginning of the study. All subjects were examined in detail for Onchocerca nodules and the locations of the nodules were recorded on anatomical diagrams. One year after the last ivermectin treatment (364 days), one skin snip was taken from each iliac crest using a 2 mm Holth-type corneo-scleral punch, by the same member of the study team, who was experienced with conducting skin snips, to maintain consistency. A second annual ivermectin treatment was then given during the study, as part of Ghana Onchocerciasis Control Program, to all subjects at 150µg/kg body weight. The final skin snips were then taken by the same operator only from subjects who were nodulectomised 90 days after the second IVM treatment. Skin snips were placed in 96-well microtitre plates containing a few drops of physiological saline solution, incubated for 24 hours and microfilariae that had emerged were counted using a dissecting microscope. The average of the microfilarial counts from the two sites was taken as the intensity of infection for each subject expressed as microfilariae/snip. Nodulectomies were performed 90 days following the second ivermectin treatment, i.e. day 455 after the first study treatment. Using local anesthesia, all palpable Onchocerca nodules were aseptically excised from 140 patients from the 10 endemic communities. Nodules were stored in liquid nitrogen until ready for digestion. Nodules were dressed free of extraneous tissue and placed in 50 ml tubes containing 10 ml of 0.5% collagenase (in sterile medium 199 solution) for digestion at 37°C in a shaking water bath for 10–24 hours. Adult worms were harvested after washing with sterile normal saline solution, and under a dissecting microscope, the viability and morphological age of worms at the time of nodulectomy were scored and intact/viable female worms prepared for embryogramme analysis. Worms were classified as alive prior to nodulectomy based on intact internal morphology, motility of the worms, and the condition of the uterine musculature Broken or ruptured worms were not examined for embryogrammes. The age of the worms was estimated based on the morphology, including the color and size of the female worms, the prominence of cuticular ridges and the degree of inclusions [10], [11], [25]. In addition to the above criteria, small and transparent worms were scored as young, opaque and yellowish as middle aged, and large and brown as older [25], [26]. Each intact female worm was cut into small pieces, two millilitres of fresh sterile medium 199 was added and worms homogenized using a toughened glass test tube mortar and pestle. By turning the pestle gently, the embryonic stages were squeezed out of the pieces of worms and embryogrammes constructed [27]. The homogenate was transferred to a Fuchs-Rosenthal counting chamber and all embryonic stages assessed as described previously [26], [27]. Quantitative assessment of normal and abnormal forms of each embryonic stage up to stretched microfilariae was done to determine the reproductive status and microfilarial content of each individual female worm [28]. Data Management and Statistical Analysis After data verification, the mean microfilarial density (mf/snip) at each time point and the density as a percentage of the initial count were determined for each community. The number of subjects in each community whose skin mf densities were greater than, the same as, or less than the initial density, or who were skin snip negative, was defined, as well as the number of subjects with greater than 10 mf/snip at day 364. Based on skin mf repopulation (early reappearance of microfilariae in the skin at day 90 and/or day 180 post-IVM treatment determined in the initial study), the mf recovery rate (skin mf density, at day 364, as a percentage of the initial count) and the distribution of the number of subjects with >10 mf/snip at day 364, communities were reclassified into four response categories (good, intermediate, poor, and the pre study ivermectin-naïve that was used as the comparator group). The intermediate response category shared some of the response characteristics of the poor response category, but not all of the characteristics. The nodule data for the communities in each response category were pooled separately and these pooled data sets were used for the analysis of the findings in the embryogrammes. Comparisons of microfilarial densities, mf recovery at day 364 and mf repopulation at day 455 (90 days after the second study IVM treatment) between the 10 communities were carried out on log transformed data using the Kruskal-Wallis non-parametric test and pair-wise comparisons by the non-parametric Mann-Whitney test. Comparison between the 10 communities in terms of nodule characteristics and worm density and between the IVM response categories regarding prevalence, reproductive activity of adult female worms and embryogramme analysis were carried out using the Chi-square test or Fisher's exact test where appropriate. Differences were considered as significant at p 10 mf/s at day 364 across the communities and the mf repopulation 90 days after the second IVM treatment during the study (day 455) in the 140 subjects that participated in the nodulectomies. The mf recovery rate for the various communities is summarized in Table 1. This shows that the microfilaria recovery rate was less than 80% in four of the five multidosed communities previously classified as good responders; the exception was Asubende which had a recovery rate of 103.8%. Three of the four communities previously classified as poor responders, had microfilaria recovery rates of more than 110%; the exception was Wiae with 99.1%. 10.1371/journal.pntd.0000998.t001 Table 1 Densities of O. volvulus microfilaria before, and at 364 days after treatment, in each community. Community No. of treatments No. of subjects examined on day -7 N  =  268 Microfilaria/snip at Day -7 Day 364 post-treatment Density % of day -7 * (recovery rate) Senyase 18 10 1.69 1.21 71.6 Beposo 18 10 2.24 1.62 72.3 Hiampe 17 17 3.03 2.37 78.2 Baaya 18 20 1.38 0.91 65.9 Asubende 19 12 2.40 2.49 103.8† Wiae 10 22 3.42 3.39 99.1† Kyingakrom 17 27 6.40 7.41 115.8‡ New Longoro 17 62 5.73 6.32 110.3‡ Jagbenbendo 12 51 8.17 9.22 112.9‡ Begbemdo¶ 1 37 30.74 12.89 41.9§ Geometric mean densities (mf/skin snip) in the ten Ghanaian communities participating in the study. *Data for % of day -7 are based on the subjects that participated at all sampling times up to day 364. †: p 10 mf/s % (No.) of subjects with day 364 mf density: > 100% of pre-treatment The same as pre-treatment (100%) Less than pre-treatment mf density (0-99%) Reduced to zero (0%) > 10 mf/s Senyase 10 10 (1) 0 20.0 (2) 80.0 (8) 20.0 (2) 0 Beposo 10 10 (1) 0 20.0 (2) 80.0 (8) 20.0 (2) 0 Hiampe 17 17.6 (3) 5.9 (1) 23.5 (4) 70.6 (12) 11.8 (2) 11.8 (2) Baaya 20 5 (1) 5.0 (1) 35.0 (7) 55.0 (11) 20.0 (4) 5(1) Asubende 12 16.7 (2) 33.3 (4) n/s 16.7 (2) 50.0 (6) 16.7 (2) 16.7 (2) Wiae 22 22.7 (5)3 27.3 (6) n/s 27.3 (6) 45.5 (10) 13.6 (3) 22.7 (5)4 n/s Kyingakrom 27 40.7 (11)6 51.9 (14) § 22.2 (6) 25.9 (7) 3.7 (1) 48.1 (13)10 § New Longoro 62 25.8 (16)7 40.3 (25) § 24.2 (15) 32.3 (20) 3.2 (2) 30.6 (19)10 § Jagbenbendo 51 37.3 (19)9 43.1 (22) § 25.5 (13) 31.4 (16) 3.9 (2) 43.1 (22)14 § Begbomdo¶ 37 81.1 (30)29 2.7 (1) 0 97.3 (36) 2.7 (1) 70.3 (26)13 § Three variables, proportion of individuals having (a) greater than pretreatment mf density, (b) same as pre-treatment mf density, and (c) less than pre-treatment mf density, were compared in the 10 communities. Kyingakrom, New Longoro and Jagbenbendo (poor responding communities) were significantly higher (§ p 20 mf/s. A further comparison examined the number of subjects with >10 mf/s at day 364 across the communities (Table 2). There were 3/57 (5.3%) for Baaya, Beposo, Senyase, Hiampe, the good responding communities 7/34 (20.7%) for Asubende and Wiae and 54/140 (38.6%) for Kyingakrom, New Longoro and Jagbenebendo, the poor response communities. The pre-study IVM-naïve community, which at day 364 post the first treatment during the study had only received a single IVM treatment, had 26/37 (70.3%) subjects with >10 mf/s. The difference between the good response and Asubende-Wiae communities was not significant (p = 0.197). However the proportion of subjects with >10 mf/s in the good response communities was significantly lower than in the poor response and the IVM-naive communities (p 10 mf/s at day 364 and, given the IVM treatment history, would satisfy the field definition of suboptimal responders [13]. Though this does not differ significantly from 25.5% (59/231) of the multi-dosed subjects who had >10 mf/s at the beginning of the study (Table 2), the good response communities had a significant reduction in the proportion of subjects who had >10 mf/s from 10.5% (6/57) at day -7 to 5.3% (3/57) at day 364. For the Asubende-Wiae communities, there were no changes, but the poor response communities showed a slight increase in the proportion of subjects who had >10 mf/s, from 32.9% (46/140) at day -7 to 38.6% (54/140) at day 364 and those who had >20 mf/s from 15.7% (22/140) to 24.3% (34/140). The determination of the skin mf repopulation 90 days after the second IVM treatment during the study (day 455) on the 140 subjects that participated in the nodulectomies is summarized in Table 3. The overall result was similar to that reported for the day 90 mf repopulation observed in the same group of individuals from the ten communities in the first phase of the study (15). We observed no skin mf repopulation in the four good response communities but a small repopulation (2.9% of pretreatment count) in the prestudy naïve community. In each of the three poor response communities the level of skin mf repopulation was greater after the second study treatment (day 455) than after the first study treatment (day 90), but the differences were not significant. 10.1371/journal.pntd.0000998.t003 Table 3 Densities and microfilaria repopulation rates after first (day 90) and second ivermectin treatments (day 455). Community No. of treatments at study end No. of subjects nodulectomized and skin snipped day 455N = 140 Microfilaria*/snip at day -7 Day 90mf/s (% day -7) Day 364 Day 455mf/s (% day 364) Senyase 18 8 1.9 0 (0) 1.3 0 (0) Beposo 18 5 2.4 0 (0) 1.7 0 (0) Hiampe 17 7 3.3 0.06 (0.02) 2.2 0 (0) Baaya 18 6 1.9 0 (0) 1.2 0 (0) Asubende 19 5 3.2 0 (0) 3.38 0.08 (0.02) Wiae 10 10 4.1 0.28 (6.8) 4.0 0.2 (5.0) Kyingakrom 17 20 7.9 1.7 (21.5) † 9.1 2.1 (23.1) † New Longoro 17 20 7.2 0.63 (8.8) † 8.1 0.99 (12.2) † Jagbenbendo 12 39 8.2 0.94 (11.5) † 9.16 1.1 (12.0) † Begbemdo ¶ 2 20 44.2 1.4 (3.2) 17.3 0.5 (2.9) Geometric mean densities (mf/skin snip) of O. volvulus microfilaria and repopulation rates observed at day 90 following the first study IVM treatment (day 90) and second IVM treatment (day 455) in the 10 onchocerciasis endemic communities studied in Ghana. *All data are based only on the subjects that were nodulectomized. At days 90 after the first study treatment and day 90 after the second study IVM treatment (i.e., day 455), there were no differences in skin mf repopulation (mf count as a % of pre-treatment) between five communities (Senyase, Beposo, Hiampe, Baaya and Begbomdo – good response or naive communities). However, three communities (New Longoro, Jagbenbendo and Kyingakrom) had significantly higher († p 10 mf/s at day 364 across the communities were examined. Our results showed that day 364 post treatment skin microfilaria levels of good response communities, including the IVM-naïve community, were below pre-treatment levels, while the poor response communities were above pre-treatment counts, with the intermediate response communities showing mf densities around pretreatment levels. Studies have shown that irrespective of the initial levels of pre-treatment microfilarial load, repeated annual treatment with IVM for five years or more results in reduction of microfilarial loads to a mean microfilaria density of less than 10 mf/s one year after the fourth or fifth treatment [9], [29], [30]. The classical observation is the study by Alley and others [29] who, using skin snip methodology similar to that employed in this study, consistently followed up more than 260 subjects every year after each treatment for five years. They observed a drastic reduction in the mean microfilaria counts from >90 mf/s to 10 mf/s to as high as 16.54 mf/s. Furthermore, considering the distribution of microfilarial loads of individual subjects in each community (Table 2) we observed significantly higher proportions (30–48%) of subjects in poor response communities having >10 mf/s as compared to 16–23% in the intermediate response communities and 0–12% in the good responding communities despite repeated ivermectin treatments over more than 10 years. Awadzi and others [13] defined sub-optimal responders as individuals who still had at least 10 mf/snip after nine or more treatments with ivermectin. It should be noted that even in two of the good response communities we observed that one or two individuals had mf loads slightly above 10 mf/s and we believe that even in the good responding communities there may be some parasites in a few individuals showing a poor response to IVM. The use of the >10 mfs/snip criterion in assessing recovery rates is particularly useful as it is independent of initial mf densities and of percentage change in initial densities. Additional skin snip data obtained 90 days (day 455) after a second dose of IVM treatment during the study, confirmed the earlier observation of rapid skin mf repopulation in the poor response communities. The skin snip data and their analysis permit the conclusion that a higher than expected return of mf to the skin occurred in some communities. The explanation for this finding is that either the adult female worms have become unresponsive or resistant to the suppressive effects of multiple doses of IVM or that new infections from ongoing transmission could account for the higher than expected rate of repopulation of the skin with microfilariae. This latter possibility was statistically analyzed [31] and the conclusion was reached that the patterns in the communities showing sub-optimal responses could not be explained by new infections. Furthermore, the distinction between the higher than expected microfilarial repopulation rates due to new infections or due to resistance of the adult worms to the effects of ivermectin on reproduction can also be made on the basis of the examination of the age distribution and embryogrammes of the adult worms. On the basis of the age distribution of the adult female worms, the embryogrammes and the statistical analysis [31], the only explanation for the rapid repopulation rates seen in the poor response communities is that individual worms exist in these communities which do not respond as expected to ivermectin. Repeated IVM treatment has marked effects on nodule numbers, morphology and composition, on adult female worm fertility and a less marked effect on adult worm vitality. Additionally, a reduction in transmission results in a decrease in new infections [3], [5]. Klager and others [11] reported a marked tendency towards smaller nodules and fewer live females per nodule with increasing length of exposure to ivermectin. They also showed that the geometric mean number of worms per nodule and total live female and male worms per nodule were significantly reduced after 10 doses of IVM. For our study, all treated communities had received at least ten years of annual IVM treatment and we expected a similar effect of ivermectin on the viability of both nodules and adult worms. However, our results showed significant differences between the good and poor response communities. In the good response communities, more than 65% of nodules were calcified and contained a mean of 0.35 female and 0.16 male worms per nodule (Table 4). On the other hand the average numbers of male and female adult worms per nodule in the poor response communities were similar to those in the pre-study IVM-naïve community. In view of the fact that there were few young worms which could suggest recent infection, this result suggests a non response or resistance to multiple doses of IVM. The proportions of older (62–78%) and middle aged worms (22–30%) in all three community response categories were similar. There were only 5% and 8% of young worms in the poor and intermediate response communities, respectively, and none in the good response communities. Additionally, the most reproductively active group was the middle aged worms followed by the older and then the young female worms. We conclude that the major contributors to the skin mf population are not the young adult worms. They must of necessity be the worms that are a few to many years older than the young worms. Since these are the worms that must have been exposed to multiple treatments with IVM in their lifetime (and two IVM treatments during the study itself) they represent non responders or worms that are resistant to the suppressive effects of multiple doses of IVM on mf production. However, the high proportion of degenerate stretched mf in utero found in all communities indicates the retention of the ability of IVM to prevent the release of the mf in some worms. It has been suggested [32], [33], that an alternative explanation for the high skin microfilarial repopulation rates is the occurrence of repeated re-infections due to poor coverage in the study communities and in surrounding communities. However, all of the communities categorized as poor or intermediate responders had good records of treatment coverage. While treatment coverage in some communities in the East Gonja district (where the pre-study treatment naïve community is found) may have been poor, coverage in surrounding communities in the Atebubu and Kintempo districts was generally good (Osei-Atweneboana and Prichard, unpublished). The mechanism underlying the alternate hypothesis must be the recruitment of significant numbers of new adult worms that would account for the skin mf load. Notably, the embryogrammes from the multi-dosed communities showed a dearth of young adult worms at a modest level of reproductive activity. These findings do not support the alternative hypothesis, nor does the analysis of the annual transmission rate that would be required to account for the skin mf repopulation rates observed in the poor responder communities [31]. However, support for the alternate hypothesis can be found in the pre-study IVM-naïve community where coverage was poor and where there were a relatively high proportion of young adult female worms (21%) as compared to 5% in the poor responding communities. It is also of interest that in this example of poor coverage in the treatment naïve community, the recovery rate of skin mf count 364 days after IVM treatment was only 41.6% of pre-treatment mf count, in contrast to the situation seen in the poor responder communities where the recovery rates were all well in excess of 100% of pre-treatment mf counts. The evidence from the initial and follow up studies enable a description of the non response or resistance phenotype to multiple treatment with IVM as follows: a) the microfilaricidal response is normal, b) there is early skin microfilarial repopulation, high microfilarial recovery rates one year post ivermectin treatment and many subjects with more than 10 mf/snip, and c) many live microfilariae are present in utero in female worms recovered 90 days after treatment. The discovery of such a phenotype should lead to a reevaluation of control strategies in order to prevent the spread of the phenomenon, and a search for the genotypic correlate that would unequivocally confirm the development of resistance. From our studies and evidence from other studies [13], [14], [34], we propose differing patterns of adult female O. volvulus responses to repeated rounds of ivermectin treatment. The three response patterns observed are: fully responsive, partial or incomplete response, and non-responsive. The fully responsive is manifested as female worms showing complete cessation of embryogenesis leading to amicrofilaridermia for prolonged periods; any microfilariae detected in a subject harboring only such parasites must originate from an external source (e.g. migration of infected individuals into the community). These parasites fall into “category 1”. The second response pattern is the partial or incomplete response. This involves incomplete cessation of embryogenesis in some female worms, resulting in intermittent low level microfilariadermias beginning six or more months after IVM treatment. These parasites fall into “category 2”. The third response pattern, non-responders, shows minimal interruption in embryogenesis with active intra-uterine mf production associated with rapid repopulation of skin and high recovery rates (“category 3” responders). Of these, a subgroup (category 3a in Figure 2) retained the ability to sequestrate mf in utero. Because of this effect, skin mf do not rise precipitously and abnormal levels of repopulation are only detected three or more months after treatment. The embryogramme shows high levels of microfilarial production associated with the accumulation of a high proportion of degenerate intrauterine mf. In category 3b, a high level of mf production is associated with a low proportion of degenerate intra-uterine mf because the block to their release has been lost and the ivermectin effect is reduced to being only a microfilaricide. There are massive increases in the skin mf soon after one month post-treatment (Awadzi, unpublished). Category 3 responses are likely to allow for parasite transmission for much of the year following ivermectin treatment. It is possible that all of these patterns of response may occur in different communities and the community response category is determined by the proportional distribution of the various adult worm response patterns. The proposed patterns of O. volvulus response have been summarized in Figure 2. It is likely that the mechanism of microfilaricidal action of IVM is distinct and separable from the inhibition of the release of mf from the uterus and the suppressive effects of ivermectin on the adult female worm. 10.1371/journal.pntd.0000998.g002 Figure 2 Response profiles of microfilaria and female O. volvulus to repeated exposure to ivermectin. At the moment the prevalence of functional blindness, as described by Kennedy and other [30], is almost absent in the study communities, except for a few blind older members of the communities. However, since the risk of developing ocular lesions and blindness is directly related to the intensity of infection [35], [36] it is important to establish strict monitoring of onchocerciasis pathology. Unfortunately, due to a lack of monitoring, the extent of the non response of the adult female worms and the influence it may have on the control of onchocerciasis in areas subjected to annual treatments are at present unknown. Supporting Information Checklist S1 STROBE checklist. (0.08 MB DOC) Click here for additional data file.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis.

              The broad-spectrum antiparasitic drug ivermectin was licensed for use against onchocerciasis in 1987, yet the mechanisms by which it exerts a fast decrease and long-lasting suppression of Onchocerca volvulus microfilaridermia, and inhibition of microfilarial release by female worms remain largely unknown. A better understanding of the effects of ivermectin on O volvulus microfilariae and macrofilariae is crucial to improve our ability to predict the long-term effect of treatment. We did a systematic review of individual and population-based ivermectin trials to investigate the temporal dynamics of the drug's microfilaricidal and embryostatic efficacy after administration of a single, standard dose (150 microg/kg). Meta-analyses on data from 26 microfilarial and 15 macrofilarial studies were linked by a mathematical model describing the dynamics of potentially fertile female parasites to skin microfilariae. The model predicts that after treatment, microfilaridermia would be reduced by half after 24 h, by 85% after 72 h, by 94% after 1 week, and by 98-99% after 1-2 months, the latter also corresponding to the time when the fraction of females harbouring live microfilariae is at its lowest (reduced by around 70% from its original value). Our results provide a baseline microfilarial skin repopulation curve against which to compare studies done after long-term treatment.
                Bookmark

                Author and article information

                Contributors
                Journal
                Int J Parasitol Drugs Drug Resist
                Int J Parasitol Drugs Drug Resist
                International Journal for Parasitology: Drugs and Drug Resistance
                Elsevier
                2211-3207
                19 May 2016
                December 2016
                19 May 2016
                : 6
                : 3
                : 272-286
                Affiliations
                [1]UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, 20 Avenue Appia, 1211 Geneva, Switzerland
                Article
                S2211-3207(16)30015-X
                10.1016/j.ijpddr.2016.04.002
                5196484
                27693536
                d139fc17-b92a-4085-bab4-b19e6d1d2af6
                © 2016 World Health Organization

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/igo/).

                History
                : 20 February 2016
                : 20 April 2016
                Categories
                Invited Review

                onchocerciasis,elimination,africa,discovery,drug development,implementation research

                Comments

                Comment on this article